Matching articles for "Prevnar 13"
Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • August 4, 2025; (Issue 1734)
...
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old
Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • August 4, 2025; (Issue 1734)
...
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old
Pneumococcal Vaccine for Adults
The Medical Letter on Drugs and Therapeutics • October 29, 2012; (Issue 1402)
The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), even if they...
The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), even if they have already received the older 23-valent unconjugated vaccine (PPSV23; Pneumovax 23). Prevnar 13, initially approved by the FDA for use in infants and young children, has been licensed since December 2011 for adults ≥50 years old.
An Expanded Pneumococcal Vaccine (Prevnar 13) for Infants and Children
The Medical Letter on Drugs and Therapeutics • August 23, 2010; (Issue 1345)
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for
the prevention of invasive pneumococcal disease (IPD) in infants and children...
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for
the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces
Prevnar (PCV7). An unconjugated 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 – Merck) is FDA-approved for use in adults.